SAN 
                ANTONIO (April 26, 2010) —  
                The findings 
                  were published April 26 in the Journal of Clinical Investigation. 
                  The senior investigator was Kenneth Hargreaves, D.D.S., Ph.D., 
                  professor and chair of the Department of Endodontics in the 
                  Dental School at the UT Health Science Center. Amol M. Patwardhan, 
                  M.B.B.S., Ph.D., a graduate of the Health Science Center's Department 
                  of Pharmacology who worked under Dr. Hargreaves' supervision, 
                  is the lead author.
                "Nearly 
                  everyone will experience persistent pain at some point in their 
                  lifetime," Dr. Hargreaves said. "Our findings are truly exciting 
                  because they will offer physicians, dentists and patients more 
                  options in prescription pain medications. In addition, they 
                  may help circumvent the problem of addiction and dependency 
                  to pain medications, and will have the potential to benefit 
                  millions of people who suffer from chronic pain every day."
                A 'complex 
                  epidemic'
                Pain has 
                  been called a "complex epidemic" in the United States. Nearly 
                  50 million Americans live with chronic pain caused by disease 
                  or injury. Few physicians or dentists specialize in the field 
                  of pain medicine. With pain medication options largely limited 
                  to opioids (such as morphine) and aspirin-like drugs, some patients 
                  become addicted or dependent upon these drugs, or suffer side 
                  effects such as kidney or liver damage. 
                Researchers 
                  at the UT Health Science Center found a new family of fatty 
                  acids, produced by the body itself, that play an important role 
                  in the biology of pain. 
                "Capsaicin 
                  is an ingredient in hot chili peppers and causes pain by activating 
                  a receptor called transient potential vanilloid 1 (TRPV1). We 
                  started out seeking the answer to the question "Why is TRPV1 
                  consistently activated in the body upon injury or painful heat? 
                  We wanted to know how skin cells talk to pain neurons," Dr. 
                  Hargreaves said. "What we found was much more surprising and 
                  exciting. We have discovered a family of endogenous capsaicin-like 
                  molecules that are naturally released during injury, and now 
                  we understand how to block these mechanisms with a new class 
                  of non-addictive therapies."
                The hot 
                  chili pepper effect
                Researchers 
                  used flaps of skin from laboratory mice that were heated in 
                  a water bath at temperatures greater than 43 degrees Celsius. 
                  The degree of heat used was significant because the human body 
                  normally begins to feel discomfort and pain at 43 degrees Celsius 
                  and higher, Dr. Hargreaves noted.
                TRPV1 resides 
                  on the membranes of pain- and heat-sensing neurons. When a person 
                  eats a hot chili pepper, for example, he immediately feels a 
                  burning sensation because the capsaicin, the primary ingredient 
                  in the chili pepper, has activated the TRPV1 protein in the 
                  pain neurons. In high concentrations, capsaicin can also cause 
                  a burning effect on other sensitive areas of the skin.
                The fluid 
                  from the heated skin was then applied to sensory neurons cultured 
                  from two sets of laboratory mice, including one set of animals 
                  in which a gene was deleted or "knocked out." Neurons from the 
                  wild type (non-altered) mice were sensitive to capsaicin, the 
                  main ingredient in chili peppers. The neurons of the knockout 
                  mice, in which the TRPV1 gene was deleted, were not sensitive 
                  to capsaicin and were used as the control.
                "We found 
                  that in the skin flaps heated at greater than 43 degrees Celsius, 
                  the cells' pain neurons showed tremendous activity in the wild 
                  type, but not in neurons from mice that lacked TRPV1," Dr. Hargreaves 
                  said. He indicated that this novel phenomenon was taking place 
                  because the cells, in response to the heat, began to create 
                  their own natural endogenous capsaicins, which they later identified 
                  as a series of compounds or fatty acids called oxidized linoleic 
                  acid metabolites (OLAMs). 
                Linoleic 
                  acid is one of the most abundant fatty acids in the human body. 
                  Under conditions such as inflammation, low blood pressure and 
                  some other illnesses, linoleic acid is rapidly oxidized to form 
                  biologically active metabolites. However, little else is understood 
                  about these substances. The metabolites that were consistently 
                  seen in increased amounts in the mouse skin biopsies exposed 
                  to heat temperatures greater than 43 degrees Celsius are called 
                  9- and 13-HODE (hydroxyoctadecadienoic acid).
                'Major 
                  breakthrough'
                "This is 
                  a major breakthrough in understanding the mechanisms of pain 
                  and how to more effectively treat it," Dr. Hargreaves said. 
                  "These data demonstrate, for the first time, that OLAMs constitute 
                  a new family of naturally occurring capsaicin-like agents, and 
                  may explain the role of these substances in many pain conditions. 
                  This hypothesis suggests that agents blocking either the production 
                  or action of these substances could lead to new therapies and 
                  pharmacological interventions for various inflammatory diseases 
                  and pain disorders such as arthritis, fibromyalgia and others, 
                  including pain associated with cancer." 
                The research 
                  has led Dr. Hargreaves' team to develop two new classes of analgesics 
                  using drugs that either block the synthesis of OLAMs or antibodies 
                  that inactivate them. These drugs could eventually come in the 
                  form of a topical agent, or a pill or liquid that could be ingested, 
                  or in the form of an injection. Both approaches have the potential 
                  to block pain at its source, unlike opioid narcotics that travel 
                  to the brain and affect the central nervous system.
                 
                
-----
                
                Co-authors 
                  of the study with Drs. Hargreaves and Patwardhan from the UT 
                  Health Science Center San Antonio are: Armen N. Akopian, Ph.D., 
                  assistant professor of endodontics; Anibal Diogenes, D.D.S., 
                  Ph.D., assistant professor of endodontics; Susan Weintraub, 
                  Ph.D., professor of biochemistry; Nikita Ruparel, D.D.S., Ph.D., 
                  a graduate student in the Department of Cellular and Structural 
                  Biology, and Charis Uhlson, a research associate at the University 
                  of Colorado Health Sciences Center. Robert Murphy, Ph.D., professor 
                  of pharmacology at the University of Colorado Health Sciences 
                  Center, is also a co-author.
                Contact: 
                  Will Sansom
                  sansom@uthscsa.edu
                  210-567-2579
                  University of Texas Health 
                  Science Center at San Antonio